论文部分内容阅读
骨质疏松症是一种多因素导致的全身代谢性骨骼疾病，骨转换失衡是其重要的病理机制。骨质疏松症的治疗靶点主要集中在抑制破骨细胞的活性及促进成骨细胞的形成方面。随着成骨及破骨细胞对骨作用的分子间信号通路等骨生物学研究的深入，一些新的治疗靶点被陆续发现。目前，较有前途的新的治疗药物主要有抗核因子κB 受体活化因子配体单克隆抗体狄诺塞麦，组织蛋白酶 K 抑制剂奥达卡替和 ONO－5334，Src 激酶抑制剂沙拉替尼等。“,”Osteoporosis is a systemic metabolic bone disease caused by multiple factors.Imbalance of bone remodeling is the fundamental pathogenesis of osteoporosis .Therefore the treatment target of osteoporosis focuses on osteoclast inhibitor and osteoblast enhancer.A sufficient understanding of bone biology with mole-cules signaling to the communication between bone-resorbing osteoclasts and bone-forming osteoblasts has led to some new discoveries of therapeutic targets.Presently the promising treatments include:denosumab,a mon-oclonal antibody against receptor activator of NF-κB ligand;odanacatib and ONO-5334,a specific inhibitor of osteoclast protease cathepsin K and saracatinib,a Src kinase inhibitor.